Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
Authors
Matthew H. Taylor
Oregon Health & Science University, Portland, OR
Matthew H. Taylor, Nicholas J. Vogelzang, Allen Lee Cohn, Daniel E. Stepan, Robert Charles Shumaker, Corina E. Dutcus, Matthew Guo, Emmett V. Schmidt, Drew W. Rasco
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02501096
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 15)
DOI
10.1200/JCO.2019.37.8_suppl.15
Abstract #
15
Poster Bd #
A8
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.
First Author: Marcia S. Brose
Poster
2018 ASCO Annual Meeting
A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
First Author: Matthew H. Taylor
Poster
2019 ASCO Annual Meeting
Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti–PD-1/PD-L1 agents: Phase 2 LEAP-004 study.
First Author: ANA Maria Arance Fernandez
Poster
2020 ASCO Virtual Scientific Program
Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Lillian L. Siu